Hulgan T - Search Results

1

Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report.

Qian HZ, Mitchell VJ, Bebawy S, Cassell H, Perez G, McGowan CC, Sterling TR, Vermund SH, D'Aquila R, Hulgan T. Qian HZ, et al. Among authors: hulgan t. BMC Infect Dis. 2014 Sep 18;14:508. doi: 10.1186/1471-2334-14-508. BMC Infect Dis. 2014. PMID: 25234368 Free PMC article.

2

Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy.

Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW. Hulgan T, et al. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):119-26. doi: 10.1097/00126334-200310010-00001. J Acquir Immune Defic Syndr. 2003. PMID: 14526200

3

Oxidant stress is increased during treatment of human immunodeficiency virus infection.

Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW. Hulgan T, et al. Clin Infect Dis. 2003 Dec 15;37(12):1711-7. doi: 10.1086/379776. Epub 2003 Nov 19. Clin Infect Dis. 2003. PMID: 14689356

4

The Role of Baseline HIV-1 Resistance Testing in Patients with Established Infection.

Chan SY, Hulgan T, D'Aquila RT. Chan SY, et al. Among authors: hulgan t. Curr Infect Dis Rep. 2004 Jun;6(3):243-249. doi: 10.1007/s11908-004-0015-4. Curr Infect Dis Rep. 2004. PMID: 15142489

5

Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons.

Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W. Hulgan T, et al. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):277-82. J Acquir Immune Defic Syndr. 2005. PMID: 15735444

6

CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.

Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR. Hulgan T, et al. J Infect Dis. 2005 Sep 15;192(6):950-7. doi: 10.1086/432955. Epub 2005 Aug 15. J Infect Dis. 2005. PMID: 16107946

7

Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.

Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR. Hulgan T, et al. J Infect Dis. 2007 Feb 1;195(3):425-31. doi: 10.1086/510536. Epub 2006 Dec 21. J Infect Dis. 2007. PMID: 17205482

8

Agreement of decision analyses and subsequent clinical studies in infectious diseases.

Bress JN, Hulgan T, Lyon JA, Johnston CP, Lehmann H, Sterling TR. Bress JN, et al. Among authors: hulgan t. Am J Med. 2007 May;120(5):461.e1-9. doi: 10.1016/j.amjmed.2006.08.032. Am J Med. 2007. PMID: 17466659 Free PMC article.

9

Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.

Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR; AIDS Clinical Trials Group 384 and A5005s Study Teams. Hulgan T, et al. J Infect Dis. 2008 Mar 15;197(6):858-66. doi: 10.1086/528697. J Infect Dis. 2008. PMID: 18419350 Clinical Trial.

10

Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators.

Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T. Shepherd BE, et al. Among authors: hulgan t. J Clin Epidemiol. 2009 Jul;62(7):729-37. doi: 10.1016/j.jclinepi.2008.09.002. Epub 2008 Dec 23. J Clin Epidemiol. 2009. PMID: 19108987 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters